To evaluate the safety and efficacy of fixed dose combination of Olmesartan and Metoprolol succinate ER in hypertensive patients with Cardiovascular Disease (CVD).

Glenmark Pharmaceuticals Limited0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•?All CVD patients (prior MI, ACS, PCI, CABG) with hypertension
•?All CVD patients (prior MI, ACS, PCI, CABG) with Uncontrolled hypertension (BP > 140/90 mmHg for hypertensive patients and BP > 130/80 mmHg for hypertensive patients with Diabetes or renal disease).

•?Not willing to provide written informed consent and comply with the protocol
•?Age below 18 years and above 65 years
•?Secondary hypertension
•?Patients requiring concomitant anti-hypertensive medications other than angiotensin receptor blockers (ARBs) or Metoprolol
•?Uncontrolled diabetes mellitus
•?Baseline laboratory values outside the clinically acceptable limits
•?Pregnant women and lactating mothers
•?Females of child bearing age not practicing contraception or not willing to use barrier contraceptive
•?Known hypersensitivity to Olmesartan/Metoprolol
•?Patients with effort angina more than class II (Drugs like Nitrates, ranolazine or Trimetazidine can be used but not amlodipine or nicorandil).
•?Sick sinus syndrome or Atrioventricular block or Heart Failure

发起方